Nuburu shares to resume NYSE American trading Sept. 14 after 1-for-40 reverse split
Nuburu, Inc. said on Sept. 9 that trading in its common stock is scheduled to resume on NYSE American on Monday, Sept. 14, ending a suspension that began in mid-July. In its announcement, the company said that "following notification from NYSE Regulation, trading in the Company's common stock is scheduled to resume on NYSE American on Monday, September 14, 2026, under the ticker symbol 'BURU.'"
The suspension dates to July 17, when NYSE American LLC — not the company — issued a release saying it had determined to commence delisting proceedings against Nuburu under Section 1003(f)(v) of the NYSE American Company Guide "due to the low selling price of the common stock." That release stated that "trading in the Company's common stock will be suspended immediately," and that the exchange "will apply to the Securities and Exchange Commission to delist the Company's common shares upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision." The exchange also noted the company's right to a review of the staff determination by the Listings Qualifications Panel of the Committee for Review of the Exchange's board of directors.
Nuburu's response was a reverse stock split. In an Aug. 31 release, the company said its board had approved a 1-for-40 reverse split, effective Sept. 1 at 4:30 p.m. Eastern time, with split-adjusted trading to begin on OTC Pink on Sept. 2. The company said no fractional shares would be issued, and that the shares would carry a new CUSIP, 67021W509 — the same CUSIP cited in Wednesday's reinstatement announcement. Nuburu said the board acted under authority stockholders had previously approved.
The arithmetic in that release is stark. Nuburu said shares outstanding stood at approximately 370,493,812 before the split and would fall to approximately 9,262,345 after it. The company described the action as "specifically intended to increase the per-share trading price of NUBURU common stock to address NYSE American's prohibition on low-selling-price stock, which includes stock trading below $0.10 per share." The same release restated the exchange's July action, saying NYSE American had suspended trading on July 17 and commenced delisting proceedings based on the low selling price of the stock. The company added its own caveat: "There can be no assurance that the Reverse Split will result in a proportionate or sustained increase in the market price of NUBURU common stock."
This is the second time in 2026 that Nuburu has followed a price-driven trading halt with a reverse split. In a Feb. 17 release announcing the closing of a public offering, the company said trading had been suspended on Feb. 13 after "the trading price dropped below NYSE American's Minimum Trading Price of $0.10." It carried out a 1-for-4.99 reverse split effective Feb. 27, reducing shares outstanding from approximately 550,701,921 to approximately 110,361,106, and trading resumed on March 2.
That February financing was itself substantially dilutive. The company said the $12 million offering comprised 58,379,137 shares of common stock and 50,711,772 pre-funded warrants exercisable at $0.0001, sold at a subscription price of $0.11, together with 163,636,364 common warrants exercisable at $0.132 for six months and thereafter at $0.11 through a five-year expiration. On a fully exercised basis, the common warrants alone represented more shares than were outstanding immediately after the February split.
In the same February release, Nuburu set out the consequence of a renewed price decline in its own words: "Following the resumption of trading on March 2, to the extent the Company's stock trades below $0.10, trading in the common stock would be halted, and the Company's common stock would be delisted by NYSE American, which would significantly affect liquidity." The exchange's July 17 action followed that description.
Between the two splits, the share count moved sharply higher. Approximately 110.4 million shares were outstanding immediately after the February 1-for-4.99 split, according to the February release; approximately 370.5 million were outstanding before the September 1-for-40 split, according to the August release. Neither document attributes that increase to any particular source, and this publication has not established one. The February offering left large tranches of pre-funded and common warrants outstanding, but the fetched releases do not state how many, if any, were exercised.
Reinstatement does not resolve Nuburu's underlying financial position. Among the risks listed in Wednesday's announcement, the company cited operating losses, negative cash flow, financing needs, dilution, and "substantial doubt about the Company's ability to continue as a going concern." The same list includes "failure to satisfy applicable continued listing requirements" and the possibility of "delays or changes in the scheduled resumption of trading or related market processing" — meaning the Sept. 14 date is described by the company as scheduled rather than certain.
The announcement also flagged execution and integration risks and customer, government-procurement, supply-chain and regulatory risks. Nuburu has publicly described work in directed-energy and defense-adjacent applications for its blue-laser technology, but the reinstatement release makes no revenue, backlog or contract claims, and none should be inferred from the listing decision itself.
For holders, the mechanics are straightforward. Nuburu said: "Stockholders are not expected to be required to take any action solely in connection with the resumption of trading." Positions will be quoted on the post-split basis under the new CUSIP. The August release stated that "no fractional shares will be issued."
The distinction between the two exchanges' approaches matters here. Nasdaq's minimum bid price framework runs on a defined clock — issuers get a 180-calendar-day compliance period and must post a closing bid of at least $1.00 for a minimum of ten consecutive business days to cure, as SolarMax Technology described in an August release of its own. NYSE American's Section 1003(f)(v) is written as a low-selling-price provision under which the exchange determined to suspend and commence proceedings; neither the July exchange release nor Nuburu's subsequent announcements described a fixed cure window.
What Wednesday's notice establishes is narrow and factual: the exchange has told the company its shares may trade again, on a schedule, under a new CUSIP, after a 40-to-1 consolidation. It does not address whether the higher nominal price holds, whether further financing follows, or whether the going-concern language in the company's own risk disclosure is resolved. Investors weighing the security should read the company's periodic reports rather than the listing notice.
